• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    DermTech Announces Release Date for First-quarter 2023 Financial Results

    4/13/23 8:05:00 AM ET
    $DMTK
    Medical Specialities
    Health Care
    Get the next $DMTK alert in real time by email

    DermTech, Inc. (NASDAQ:DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, will host a conference call and webcast on Thursday, May 4, 2023 at 5:00 p.m. Eastern Time (ET) to discuss the Company's first-quarter 2023 operating and financial results. In advance of the call on May 4, 2023, DermTech will issue its first-quarter 2023 earnings press release.

    For participants interested in asking questions during the teleconference, please register using the following link. After registering for the event, a confirmation e-mail will be sent with a meeting invitation and access information. Registration is open during the live teleconference, but advance registration is advised.

    Conference Call Registration

    For participants interested in listening only, please register for the webcast using the following link.

    Webcast Registration

    For those unable to participate in the live call and webcast, a webcast replay will be available on the Company's website shortly after the conclusion of the call.

    About DermTech

    DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics platform. DermTech's mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected non-invasively using its Smart StickersTM. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information, please visit DermTech.

    Forward-Looking Statements

    This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "outlook," "anticipate," "intend," "plan," "may," "will," "could," "should," "believe," "predict," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations and evaluations with respect to: the performance, patient benefits, cost- effectiveness, commercialization and adoption of DermTech's products and the market opportunity for these products, DermTech's positioning and potential growth, financial outlook and future financial performance, ability to maintain or improve its operating efficiency and reduce operating expenses, the sufficiency of DermTech's cash and ability to access capital to fund its operating plan, implications and interpretations of any study results, expectations regarding agreements with or reimbursement or cash collection patterns from Medicare, government payers or commercial payers and related billing practices or number of covered lives, DermTech's ability to expand its product offerings and develop pipeline products, and expectations regarding the search for, transition to and future contributions of a successor CEO. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech's ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech's tests; (4) the reimbursement of DermTech's tests by Medicare, government payers and commercial payers; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech's products; (6) DermTech's ability to grow, manage growth and retain its key employees and maintain or improve its operating efficiency and reduce operating expenses; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech's products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in the "Risk Factors" section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the "SEC"), and other documents filed or to be filed by DermTech with the SEC, including subsequently filed reports. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward- looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005347/en/

    Get the next $DMTK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DMTK

    DatePrice TargetRatingAnalyst
    7/18/2022$48.00Outperform
    Oppenheimer
    6/14/2022$38.00 → $19.00Buy
    BTIG Research
    1/7/2022$26.00Overweight
    Stephens
    1/7/2022Overweight
    Stephens & Co.
    10/15/2021$50.00Outperform
    Cowen
    More analyst ratings

    $DMTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Sun Kevin M covered exercise/tax liability with 445 shares, decreasing direct ownership by 0.17% to 269,216 units (SEC Form 4)

      4 - DermTech, Inc. (0001651944) (Issuer)

      6/12/24 8:07:07 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • Akhavan Ramin covered exercise/tax liability with 3,745 shares, decreasing direct ownership by 3% to 128,425 units (SEC Form 4)

      4 - DermTech, Inc. (0001651944) (Issuer)

      6/7/24 8:06:44 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • Sun Kevin M covered exercise/tax liability with 4,945 shares, decreasing direct ownership by 2% to 269,661 units (SEC Form 4)

      4 - DermTech, Inc. (0001651944) (Issuer)

      6/7/24 8:04:16 PM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DermTech Files for Voluntary Chapter 11 Protection

      DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The chapter 11 filing is a continuation of the Company's strategic alternatives review process. Currently, the Company intends to continue its laboratory operations and processing orders for the DermTech Melanoma Test (DMT), while simultaneously conducting a process to sell substantially all of its assets. Through the bankruptcy process, the Company intends to safeguard the interest of stakeholders and maximize the value of its assets. DermTech

      6/18/24 8:05:00 AM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Reports First-Quarter 2024 Financial Results

      - Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 24 percent year-over-year - Test revenue increased 7 percent versus the first quarter of 2023 DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its first-quarter 2024 financial results. First-Quarter 2024 Financial Results Billable sample volume declined 14 percent from the first quarter of 2023 to approximately 15,360. Test revenue was $3.7 million, up 7 percent from the first quarter of 2023, primarily due to a higher ASP for the DMT. Total revenue was $3.8 million, an 11 percent increase from

      5/14/24 4:05:00 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech to Explore Strategic Alternatives and Implement Restructuring Plan

      DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring strategic alternatives to maximize stockholder value. Potential strategic alternatives that may be explored or evaluated include an acquisition, merger, reverse merger, business combination, sale of assets, licensing or other transaction involving the Company. There can be no assurance, however, that the strategic review process will result in any such transaction or if a transaction is undertaken, that such transaction would close in

      4/18/24 4:15:00 PM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer resumed coverage on DermTech with a new price target

      Oppenheimer resumed coverage of DermTech with a rating of Outperform and set a new price target of $48.00

      7/18/22 9:13:48 AM ET
      $DMTK
      Medical Specialities
      Health Care
    • BTIG Research reiterated coverage on DermTech with a new price target

      BTIG Research reiterated coverage of DermTech with a rating of Buy and set a new price target of $19.00 from $38.00 previously

      6/14/22 8:37:49 AM ET
      $DMTK
      Medical Specialities
      Health Care
    • Stephens initiated coverage on DermTech with a new price target

      Stephens initiated coverage of DermTech with a rating of Overweight and set a new price target of $26.00

      1/7/22 7:32:05 AM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    SEC Filings

    See more
    • DermTech Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - DermTech, Inc. (0001651944) (Filer)

      6/20/24 4:03:19 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Costs Associated with Exit or Disposal Activities, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - DermTech, Inc. (0001651944) (Filer)

      6/18/24 8:10:13 AM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation, Other Events

      8-K - DermTech, Inc. (0001651944) (Filer)

      5/17/24 4:05:27 PM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Leadership Updates

    Live Leadership Updates

    See more
    • DermTech, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 15, 2023 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises DermTech, Inc. ("DermTech" or the "Company") (NASDAQ:DMTK) investors that a lawsuit filed on behalf of investors that purchased DermTech securities between May 3, 2022 through November 3, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for

      11/7/23 4:13:58 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 15, 2023 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises DermTech, Inc. ("DermTech" or the "Company") (NASDAQ:DMTK) investors that a lawsuit filed on behalf of investors that purchased DermTech securities between May 3, 2022 through November 3, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options

      10/18/23 3:55:34 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Appoints Mark Aguillard as Chief Commercial Officer

      DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the appointment of Mark Aguillard as chief commercial officer effective September 19, 2023. Mr. Aguillard will lead DermTech's overall commercial strategy and execution. Commenting on Mr. Aguillard's appointment, Bret Christensen, DermTech's CEO said, "I'd like to welcome Mark to the team. We are confident that his demonstrated success and wide breadth of commercial and payer access experience will serve us well during this transformational period as we focus on generating reimbursed tests to grow revenue. Mark's leadership will be i

      9/11/23 8:05:00 AM ET
      $DMTK
      Medical Specialities
      Health Care